Robust antibody response after 3 doses of mRNA COVID-19 vaccine in hemodialysis patients

Antibody response to SARS-CoV-2 after the second and third doses of mRNA COVID-19 vaccine in Japanese hemodialysis patients - Effects after mRNA COVID-19 vaccine administration in hemodialysis patients

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000047083

Enrollment

283

Registered

2022-04-01

Start date

2021-04-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hemodialysis patients

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients on hemodialysis 3 times a week in our hospital

Exclusion criteria

Exclusion criteria: Patients with no history of COVID-19

Design outcomes

Primary

Measure	Time frame
Degree of increase in SARS-CoV-2 antibody titer after mRNA COVID-19 vaccination	—

Countries

Japan

Contacts

Public ContactRyochi Miyazaki

Fujita Memorial Hospital Internal Medicine

ryoichi@mitene.or.jp1776211277

Outcome results